Updated efficacy and safety results from phase 1 and phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease

Mark Thomas

doi:10.1016/j.ymgme.2021.11.316

Updated efficacy and safety results from phase 1 and phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S119-S119
Number of pages	1
Journal	Molecular Genetics and Metabolism
Volume	135
Issue number	2
DOIs	https://doi.org/10.1016/j.ymgme.2021.11.316
Publication status	Published - Feb 2022
Externally published	Yes
Event	18th Annual WORLD Symposium - San Diego, Canada Duration: 7 Feb 2022 → 11 Feb 2022

Access to Document

10.1016/j.ymgme.2021.11.316

Cite this

@article{f755dcd609b44837bd43794e03a9a5fc,

title = "Updated efficacy and safety results from phase 1 and phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease",

author = "Mark Thomas",

year = "2022",

month = feb,

doi = "10.1016/j.ymgme.2021.11.316",

language = "English",

volume = "135",

pages = "S119--S119",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press",

number = "2",

note = "18th Annual WORLD Symposium ; Conference date: 07-02-2022 Through 11-02-2022",

}

TY - JOUR

T1 - Updated efficacy and safety results from phase 1 and phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease

AU - Thomas, Mark

PY - 2022/2

Y1 - 2022/2

U2 - 10.1016/j.ymgme.2021.11.316

DO - 10.1016/j.ymgme.2021.11.316

M3 - Abstract/Meeting Abstract

VL - 135

SP - S119-S119

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

T2 - 18th Annual WORLD Symposium

Y2 - 7 February 2022 through 11 February 2022

ER -